Discontinued — last reported Q3 '24
Business Segments · Operating Income (Loss)
Covance Drug Development — Operating Income (Loss)
Labcorp Holdings Covance Drug Development — Operating Income (Loss) increased by 12.6% to $120.90M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 10.9%, from $109.00M to $120.90M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ3 2024
Rolls up toOperating Income
How to read this metric
An increase indicates improved operational efficiency or higher margins on service contracts.
Detailed definition
The profit or loss generated by the drug development segment after deducting operating expenses, including research, dev...
Peer comparison
Operating margin performance is a key benchmark for CRO segment efficiency across the industry.
Metric ID:
lh_segment_covance_drug_development_operating_income_lossHistorical Data
11 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $147.30M | $141.60M | $124.20M | $150.90M | $156.70M | $73.60M | $104.60M | $109.00M | $99.90M | $107.40M | $120.90M |
| QoQ Change | — | -3.9% | -12.3% | +21.5% | +3.8% | -53.0% | +42.1% | +4.2% | -8.3% | +7.5% | +12.6% |
| YoY Change | — | — | — | +2.4% | +10.7% | -40.7% | -30.7% | -30.4% | +35.7% | +2.7% | +10.9% |
Range$73.60M – $156.70M
CAGR-7.6%
Avg YoY Growth-4.9%
Median YoY Growth+2.6%
Current Streak2 quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — operating income (loss)?
- Labcorp Holdings (LH) reported covance drug development — operating income (loss) of $120.90M in Q3 2024.
- How has Labcorp Holdings's covance drug development — operating income (loss) changed year-over-year?
- Labcorp Holdings's covance drug development — operating income (loss) increased by 10.9% year-over-year, from $109.00M to $120.90M.
- What does covance drug development — operating income (loss) mean?
- The operating profit or loss specifically attributable to the drug development segment.